Enclomiphene Citrate for Secondary Hypogonadism: Evidence, Dosage, and Protocol

Clinical Evidence: Enclomiphene for Male Secondary Hypogonadism

Enclomiphene has been studied more rigorously for secondary hypogonadism than any other SERM. Unlike racemic clomiphene (which entered practice via off-label use with limited controlled trial data in men), enclomiphene underwent dedicated clinical development specifically targeting male secondary hypogonadism.

The central efficacy trial was Wiehle et al. (2014), a Phase III randomized double-blind controlled study comparing enclomiphene 12.5 mg/day, enclomiphene 25 mg/day, and testosterone 1.62% gel in 200 hypogonadal men (baseline T below 300 ng/dL) over 12 weeks. Key findings:

• Enclomiphene 25 mg normalized testosterone in 77% of subjects (testosterone gel: 81%)
• Testosterone gel suppressed LH to near-undetectable levels; enclomiphene increased LH by 65-80%
• Testosterone gel reduced total sperm count by 25%; enclomiphene increased sperm count by 14%
• Both treatments improved erectile function scores, sexual desire, and energy, with statistically similar outcomes

(Wiehle et al., 2014, doi:10.1111/andr.12150)

Kim et al. (2013) reported the Phase II data on 124 hypogonadal men. At 12 weeks, enclomiphene 12.5 mg/day increased mean testosterone from ~190 ng/dL to ~400 ng/dL, while the 25 mg/day dose achieved ~500 ng/dL. LH and FSH increased proportionally at all doses, confirming the mechanism-driven, axis-stimulating nature of the effect (Kim et al., 2013, doi:https://pubmed.ncbi.nlm.nih.gov/26496621/).

Drobnis et al. (2017) specifically examined semen parameters across the Phase III trial. Enclomiphene was associated with maintained or improved sperm concentration, motility, and morphology at all doses through 12 weeks, the opposite of testosterone gel, which caused significant spermatogenic suppression. For men with secondary hypogonadism who wish to remain fertile or restore fertility, this represents a decisive advantage.

Mechanism: How Enclomiphene Restores Testosterone in Hypogonadal Men

Secondary hypogonadism results from insufficient hypothalamic GnRH pulsatility or pituitary responsiveness, the testes are capable of producing testosterone if properly stimulated, but the upstream signals are too weak. Enclomiphene corrects this at the source.

Selective Estrogen Receptor Modulation in the Hypothalamus

Enclomiphene is a pure competitive antagonist at estrogen receptors (ER) in the hypothalamus and pituitary, with essentially none of the partial agonism that the cis-isomer (zuclomiphene) exhibits in these tissues. By blocking ER, enclomiphene prevents estradiol from suppressing GnRH pulsatility. The hypothalamus responds by increasing GnRH pulse frequency and amplitude, which drives pituitary LH and FSH secretion.

Increased Leydig Cell Stimulation

Elevated LH directly stimulates Leydig cells in the testes to synthesize and secrete testosterone. In secondary hypogonadism, the Leydig cells are typically intact and capable of robust testosterone production, they simply haven’t been receiving adequate LH signal. Enclomiphene’s mechanism restores this signal without bypassing the HPG axis.

Why Enclomiphene Is Cleaner Than Clomid for Long-Term Hypogonadism Treatment

Commercial Clomid contains zuclomiphene (38%), which has a very long half-life (~30 days) and partial ER agonism. With chronic daily dosing, zuclomiphene accumulates and can exert net estrogenic effects at some tissues, contributing to mood changes, SHBG changes, and reduced libido in a subset of men. Enclomiphene’s elimination half-life is approximately 10 hours; it does not accumulate, and each dose delivers a clean, transient antagonist pulse. For chronic daily use in secondary hypogonadism, this pharmacokinetic profile translates to more consistent and predictable responses.

Dosage Protocol for Secondary Hypogonadism

Based on Phase II/III clinical trial data:

• Starting dose: 12.5 mg/day, effective in ~70% of patients; generally well-tolerated as initial therapy
• Standard therapeutic dose: 25 mg/day, produces testosterone normalization in ~77% of patients; equivalent outcomes to testosterone gel
• Maintenance: Long-term daily use at 12.5-25 mg/day; no evidence of tachyphylaxis or declining efficacy over time in clinical trials
• Dose adjustment: If testosterone at 4 weeks is below 400 ng/dL on 12.5 mg/day, increase to 25 mg/day. If estradiol is elevated (>40 pg/mL) with symptoms, consider dose reduction or adjunct aromatase inhibitor

Monitoring: Baseline and 4-week bloodwork: total testosterone, LH, FSH, estradiol, CBC, metabolic panel. Target total testosterone 400-700 ng/dL. LH in the 3-10 IU/L range confirms appropriate axis stimulation.

Enclomiphene vs Testosterone Replacement: Key Advantages

For men with secondary hypogonadism who are candidates for either treatment, the enclomiphene vs TRT decision hinges primarily on fertility intent and preference for maintaining natural testicular function:

Outcome	Enclomiphene	Testosterone Gel
Testosterone normalization rate	77% (25 mg/day)	81%
LH/FSH at 12 weeks	+65-80% from baseline	Suppressed to near-zero
Sperm count at 12 weeks	+14% from baseline	-25% from baseline
Testicular volume	Maintained	Decreases with prolonged use
Erectile function improvement	Significant (similar to TRT)	Significant
Energy and libido improvement	Significant (similar to TRT)	Significant
Route of administration	Oral daily tablet	Daily gel application

Side Effects and Safety Profile

Enclomiphene at 12.5-25 mg/day demonstrated a favorable safety profile in Phase III trials:

• Hot flashes: ~15% of subjects, expected mechanism-based effect from hypothalamic ER blockade
• Headache: Mild, transient, typically first-week only
• No significant changes in blood pressure, hematocrit (a key safety concern with TRT), or liver enzymes in clinical trials
• Visual disturbances: Rare; significantly less frequent than with racemic clomiphene
• No negative impact on mood, libido, or sexual function, in contrast to some users’ experiences with racemic Clomid

Frequently Asked Questions

Is enclomiphene FDA-approved for secondary hypogonadism?

Enclomiphene (as Androxal) completed Phase III trials but did not receive FDA approval. The FDA requested additional studies examining cardiovascular outcomes. It remains an investigational compound used as a research chemical. Racemic clomiphene, from which enclomiphene is derived, is FDA-approved but for female infertility; its use in male hypogonadism is off-label. Canadian regulations differ, consult current Health Canada guidance for Canadian use.

How is enclomiphene different from Clomid if Clomid already contains enclomiphene?

Commercial Clomid (clomiphene citrate) is a racemate: ~62% enclomiphene + ~38% zuclomiphene. Enclomiphene as a single isomer delivers all of the HPG-stimulating action without the estrogenic carry-over from zuclomiphene accumulation. The practical difference is most pronounced with chronic daily dosing (as in hypogonadism treatment), where zuclomiphene accumulates over weeks to months and can produce estrogenic effects that compete with enclomiphene’s antagonism.

Can enclomiphene be used long-term for secondary hypogonadism?

Phase III clinical trials evaluated enclomiphene for 12 weeks with no evidence of declining efficacy or emerging safety concerns. Clinical experience with racemic clomiphene extends to 19+ months (Katz et al., 2012) in male hypogonadism with sustained testosterone normalization and preserved testicular function. There is no pharmacological reason to expect enclomiphene to lose efficacy over time, as it acts on a receptor system rather than depleting a substrate.

How to Source Enclomiphene in Canada

Elite Bio Supply carries pharmaceutical-grade Enclomiphene Citrate with domestic shipping across Canada via Canada Post. All batches are third-party tested for purity and identity. View Enclomiphene product page and order.

Related Guides

• Enclomiphene Dosage Guide
• Enclomiphene Side Effects
• Buy Enclomiphene in Canada
• Clomid for Secondary Hypogonadism
• Enclomiphene for PCT